Literature DB >> 18432738

Experimental autoimmune myasthenia gravis in the mouse.

B Wu1, E Goluszko, P Christadoss.   

Abstract

Myasthenia gravis (MG) is a T cell-dependent antibody-mediated autoimmune neuromuscular disease. Antibodies to the nicotinic acetylcholine receptor (AChR) destroy the AChR, thus leading to defective neuromuscular transmission of electrical impulse and to muscle weakness. This unit is a practical guide to the induction and evaluation of experimental autoimmune myasthenia gravis (EAMG) in the mouse, the animal model for MG. Protocols are provided for the extraction and purification of AChR from the electric organs of Torpedo californica, or eel. The purified receptor is used as an immunogen to induce autoimmunity to AChR, thus causing EAMG. The defect in neuromuscular transmission can also be measured quantitatively by electromyography, as described here. In addition, EAMG is frequently characterized by the presence of antibodies to AChR, which are measured by radioimmunoassay and by a marked antibody-mediated reduction in the number of muscle AChRs. AChR extracted from mouse muscle is used in measuring serum antibody levels and for quantifying muscle AChR content.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 18432738      PMCID: PMC3249402          DOI: 10.1002/0471142735.im1508s21

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  35 in total

Review 1.  Myasthenia gravis.

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1994-06-23       Impact factor: 91.245

2.  T-cell receptor gene usage of acetylcholine receptor-specific T-helper cells.

Authors:  A Melms; J R Oksenberg; G Malcherek; R Schoepfer; C A Müller; J Lindstrom; L Steinman
Journal:  Ann N Y Acad Sci       Date:  1993-06-21       Impact factor: 5.691

3.  Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis.

Authors:  R Kaul; M Shenoy; E Goluszko; P Christadoss
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

Review 4.  Immunogenetics of experimental autoimmune myasthenia gravis.

Authors:  P Christadoss
Journal:  Crit Rev Immunol       Date:  1989       Impact factor: 2.214

5.  Daunomycin treatment prevents clinical expression of experimental autoimmune myasthenia gravis.

Authors:  P Christadoss; R Henderson; S Keve
Journal:  Clin Immunol Immunopathol       Date:  1991-05

6.  Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody.

Authors:  M A Agius; D P Richman
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

7.  Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines.

Authors:  R Hohlfeld; I Kalies; B Kohleisen; K Heininger; B Conti-Tronconi; K V Toyka
Journal:  Neurology       Date:  1986-05       Impact factor: 9.910

8.  Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor.

Authors:  M Shenoy; M Oshima; M Z Atassi; P Christadoss
Journal:  Clin Immunol Immunopathol       Date:  1993-03

9.  The pathogenic role of acetylcholine receptor alpha chain epitope within alpha 146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice.

Authors:  M Shenoy; E Goluszko; P Christadoss
Journal:  Clin Immunol Immunopathol       Date:  1994-12

10.  HLA-DQ beta-chain polymorphism linked to myasthenia gravis.

Authors:  J Bell; L Rassenti; S Smoot; K Smith; C Newby; R Hohlfeld; K Toyka; H McDevitt; L Steinman
Journal:  Lancet       Date:  1986-05-10       Impact factor: 79.321

View more
  9 in total

1.  Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  J Autoimmun       Date:  2014-01-02       Impact factor: 7.094

2.  In vivo adsorption of autoantibodies in myasthenia gravis using Nanodisc-incorporated acetylcholine receptor.

Authors:  Jian Rong Sheng; Steve Grimme; Palash Bhattacharya; Michael H B Stowell; Michael Artinger; Bellur S Prabahakar; Matthew N Meriggioli
Journal:  Exp Neurol       Date:  2010-07-15       Impact factor: 5.330

3.  Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile.

Authors:  Huan Yang; Yong Zhang; Minghua Wu; Jing Li; Wenbin Zhou; Guiyuan Li; Xiaoling Li; Bo Xiao; Premkumar Christadoss
Journal:  Inflamm Res       Date:  2009-09-19       Impact factor: 4.575

4.  Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.

Authors:  Zhiguo Li; Minshu Li; Kristofer Wood; Steffan Hettwer; Suraj A Muley; Fu-Dong Shi; Qiang Liu; Shafeeq S Ladha
Journal:  Muscle Nerve       Date:  2018-01-08       Impact factor: 3.217

5.  Myotubular myopathy and the neuromuscular junction: a novel therapeutic approach from mouse models.

Authors:  James J Dowling; Romain Joubert; Sean E Low; Ashley N Durban; Nadia Messaddeq; Xingli Li; Ashley N Dulin-Smith; Andrew D Snyder; Morgan L Marshall; Jordan T Marshall; Alan H Beggs; Anna Buj-Bello; Christopher R Pierson
Journal:  Dis Model Mech       Date:  2012-05-24       Impact factor: 5.758

6.  Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis.

Authors:  Jindrich Soltys; Xiaobo Wu
Journal:  J Inflamm (Lond)       Date:  2012-05-29       Impact factor: 4.981

7.  Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.

Authors:  Mario Losen; Pilar Martinez-Martinez; Peter C Molenaar; Konstantinos Lazaridis; Socrates Tzartos; Talma Brenner; Rui-Sheng Duan; Jie Luo; Jon Lindstrom; Linda Kusner
Journal:  Exp Neurol       Date:  2015-03-18       Impact factor: 5.330

8.  Improved methodology to obtain large quantities of correctly folded recombinant N-terminal extracellular domain of the human muscle acetylcholine receptor for inducing experimental autoimmune myasthenia gravis in rats.

Authors:  Chenjing Sun; Hongliang Zhang; Jiang Xu; Jie Gao; Xiaokun Qi; Zhuyi Li
Journal:  Arch Med Sci       Date:  2013-08-12       Impact factor: 3.318

9.  Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study.

Authors:  Linda L Kusner; Michael J Ciesielski; Alexander Marx; Henry J Kaminski; Robert A Fenstermaker
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.